Publication Information

{'id': 'https://openalex.org/W3147989365', 'doi': None, 'title': 'Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment', 'display_name': 'Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment', 'publication_year': 2011, 'publication_date': '2011-01-01', 'ids': {'openalex': 'https://openalex.org/W3147989365', 'mag': '3147989365'}, 'language': 'zh-cn', 'primary_location': {'is_oa': False, 'landing_page_url': 'http://www.cqvip.com/QK/85656X/201115/38871853.html', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306541197', 'display_name': '中华医学杂志：英文版', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': None, 'host_organization_name': None, 'host_organization_lineage': [], 'host_organization_lineage_names': [], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': [], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5110753019', 'display_name': 'Сонг', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Song', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5070983188', 'display_name': 'Zheng-bo', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Zheng-bo', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5112028515', 'display_name': 'Yu', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Yu', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5004125284', 'display_name': 'Yongfeng', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Yong-feng', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5108741480', 'display_name': 'Chen', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Chen', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5085354408', 'display_name': 'Zhiwei', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Zhi-wei', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5110336671', 'display_name': 'Lǔ', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Lu', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5032082386', 'display_name': 'Shun', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Shun', 'raw_affiliation_strings': [], 'affiliations': []}], 'institution_assertions': [], 'countries_distinct_count': 0, 'institutions_distinct_count': 0, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 65}, 'biblio': {'volume': None, 'issue': '15', 'first_page': '2279', 'last_page': '2283'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9998, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9998, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10696', 'display_name': 'Gastric Cancer Management and Outcomes', 'score': 0.9928, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T12334', 'display_name': 'Lung Cancer Research Studies', 'score': 0.9857, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/erlotinib-hydrochloride', 'display_name': 'Erlotinib Hydrochloride', 'score': 0.64561105}], 'concepts': [{'id': 'https://openalex.org/C2778087573', 'wikidata': 'https://www.wikidata.org/wiki/Q418369', 'display_name': 'Erlotinib', 'level': 4, 'score': 0.99074024}, {'id': 'https://openalex.org/C2780580887', 'wikidata': 'https://www.wikidata.org/wiki/Q417824', 'display_name': 'Gefitinib', 'level': 4, 'score': 0.98051214}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.704621}, {'id': 'https://openalex.org/C2909325608', 'wikidata': 'https://www.wikidata.org/wiki/Q418369', 'display_name': 'Erlotinib Hydrochloride', 'level': 5, 'score': 0.64561105}, {'id': 'https://openalex.org/C2776256026', 'wikidata': 'https://www.wikidata.org/wiki/Q47912', 'display_name': 'Lung cancer', 'level': 2, 'score': 0.63283145}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.488312}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.47582868}, {'id': 'https://openalex.org/C2779438470', 'wikidata': 'https://www.wikidata.org/wiki/Q424401', 'display_name': 'Epidermal growth factor receptor', 'level': 3, 'score': 0.44737494}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.22312322}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'http://www.cqvip.com/QK/85656X/201115/38871853.html', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306541197', 'display_name': '中华医学杂志：英文版', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': None, 'host_organization_name': None, 'host_organization_lineage': [], 'host_organization_lineage_names': [], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'score': 0.56, 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': [], 'abstract_inverted_index': {'背景几临床的试用证明': [0], 'erlotinib': [1, 9, 25, 29, 48, 85, 90, 99, 105], '在在先进非小的房间肺癌症(NSCLC': [2], ')': [3, 31, 33, 35, 39, 46, 60, 62, 65, 68, 70, 72, 74, 77, 81, 83, 88], '的': [4, 20], 'gefitinib': [5, 7, 23, 37, 79, 97, 103], '的失败以后是有效的。这研究的目的是从我们的医院基于数据在': [6], '的失败以后评估': [8], '治疗的可行性。从': [10], '2007': [11], '年': [12, 16], '8': [13], '月进入上海胸医院到': [14], '2008': [15], '12': [17], '月的有先进': [18], 'NSCLC': [19], '20': [21], '个病人的临床的数据回顾地被分析的方法。所有在': [22], '的失败以后病人被给': [24], '治疗。幸存分析被': [26], 'Kaplan-Meier': [27], '方法做。艇长回归模型被执行分析在有影响的因素和': [28], '之间的关系没有前进的幸存(PFS': [30], '。结果五个病人有部分回答(PR': [32], '，九个病人有稳定的疾病(SD': [34], '，六个病人与': [36], '治疗有进步疾病(PD': [38], '。中部的': [40], 'PFS': [41, 54, 86], '是': [42, 55, 63, 66], '277': [43], '天(95%': [44, 57], 'C/0-566': [45], '。没有病人与': [47], '治疗有': [49], 'PR，七有的': [50], 'SD': [51, 92, 95], '和十四': [52], 'PD。中部的': [53], '31': [56], 'Cl': [58], '9.1-52.9': [59], '。反应率(RR': [61], '0，并且疾病控制率(DCR': [64], '35%(7/20': [67], '。考克斯回归分析表明了那性(P=0.96': [69], '，年龄(P=0.89': [71], '，吸烟历史(P=0.78': [73], '，表演地位(PS': [75], ')(P=0.98': [76], '，': [78], '功效(P=0.90': [80], '并且化疗是否用二药(P=0.45': [82], '被使用在之间，没与': [84], '有重要关联。十五个病人有因素受体(EGFR': [87], '变化地位决定了的表皮的生长。有五个盒子有在十个变化的': [89], '治疗的得到的': [91], '否定(野类型)': [93], '病人。没有': [94], '在五个变化被记录积极病人。在': [96], '失败以后的': [98], '治疗的功效被限制的结论。然而，是': [100], 'EGFR': [101], '变化的病人否定罐头可能在': [102], '以后得益于': [104], '治疗失败。': [106]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W3147989365', 'counts_by_year': [], 'updated_date': '2024-12-06T05:04:05.374868', 'created_date': '2021-04-13'}